1. A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations
by Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, and Jeffrey E. Miller
BloodAdv
Volume 2(8):
April 24, 2018
© 2018 by The American Society of Hematology

2. Mark J. Levis et al. Blood Adv 2018;2:825-831
© 2018 by The American Society of Hematology

3. Linearity of NGS-MRD assay.
Linearity of NGS-MRD assay. The NGS-MRD assay was performed using mutant DNA spiked into wild-type DNA. Two cell lines, each expressing different ITD mutations, were used (cell line A [MV4-11], 30 bp and cell line B [PL-21], 126 bp). The results of the assay were plotted after linear conversion as detected vs expected. Results of regression analysis are shown.
Mark J. Levis et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

4. OS for subjects achieving remission in the CHRYSALIS study (ASP2215-CL-0101) according to detectable MRD. Kaplan-Meier analysis of survival for subjects treated with FLT3-inhibitory doses of gilteritinib (ASP2215) who achieved a CR, CRi, or CRp, according to the presence or absence of MRD detected by the NGS-MRD assay after treatment.
OS for subjects achieving remission in the CHRYSALIS study (ASP2215-CL-0101) according to detectable MRD. Kaplan-Meier analysis of survival for subjects treated with FLT3-inhibitory doses of gilteritinib (ASP2215) who achieved a CR, CRi, or CRp, according to the presence or absence of MRD detected by the NGS-MRD assay after treatment. MRD is defined as FLT3-ITD VAF ≥10−4. CI, confidence interval; NA, not achieved.
Mark J. Levis et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology

5. OS for subjects in the CHRYSALIS study (ASP2215-CL-0101) according to molecular response.
OS for subjects in the CHRYSALIS study (ASP2215-CL-0101) according to molecular response. Kaplan-Meier analysis of survival for subjects treated with FLT3-inhibitory doses of gilteritinib (ASP2215), according to ITD VAF detected by the NGS-MRD assay after treatment.
Mark J. Levis et al. Blood Adv 2018;2:
© 2018 by The American Society of Hematology